Since the ApoA5 is a key determinant of serum TG concentrations which has been identified as a major risk factor for CAD and a biomarker for the metabolic syndrome, it is well-accepted that thyroid hormones influenced VLDL-TG metabolism through ApoA5, indicating that the identification of ApoA5 as a T3 target gene provides a new potential mechanism whereby thyroid hormones could influence serum TG homeostasis [70]. This evidence concerns the gene APOA5 and metabolic syndrome.